|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007137,
umls-concept:C0008838,
umls-concept:C0030705,
umls-concept:C0205179,
umls-concept:C0205195,
umls-concept:C0205390,
umls-concept:C0460004,
umls-concept:C1135135,
umls-concept:C1517927,
umls-concept:C1522449,
umls-concept:C2603343
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-9-27
|
|
pubmed:abstractText |
Erlotinib, an oral tyrosine kinase inhibitor, is active against head-and-neck squamous cell carcinoma (HNSCC) and possibly has a synergistic interaction with chemotherapy and radiotherapy. We investigated the safety and efficacy of erlotinib added to cisplatin and radiotherapy in locally advanced HNSCC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1879-355X
|
|
pubmed:author |
pubmed-author:AraújoCarlos Manoel MCM,
pubmed-author:BezerraMarcosM,
pubmed-author:DiasFernando LFL,
pubmed-author:FedericoMiriam HMH,
pubmed-author:FerreiraCarlos GCG,
pubmed-author:FontãoKarinaK,
pubmed-author:HerchenhornDanielD,
pubmed-author:KnustRenata ERE,
pubmed-author:MartinsRenato GRG,
pubmed-author:SmallIsabelleI,
pubmed-author:ViegasCélia M PCM
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
696-702
|
|
pubmed:meshHeading |
pubmed-meshheading:20421154-Adult,
pubmed-meshheading:20421154-Aged,
pubmed-meshheading:20421154-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20421154-Brazil,
pubmed-meshheading:20421154-Carcinoma, Squamous Cell,
pubmed-meshheading:20421154-Cisplatin,
pubmed-meshheading:20421154-Combined Modality Therapy,
pubmed-meshheading:20421154-Confidence Intervals,
pubmed-meshheading:20421154-Drug Administration Schedule,
pubmed-meshheading:20421154-Drug Eruptions,
pubmed-meshheading:20421154-Female,
pubmed-meshheading:20421154-Head and Neck Neoplasms,
pubmed-meshheading:20421154-Humans,
pubmed-meshheading:20421154-Hypopharyngeal Neoplasms,
pubmed-meshheading:20421154-Laryngeal Neoplasms,
pubmed-meshheading:20421154-Male,
pubmed-meshheading:20421154-Middle Aged,
pubmed-meshheading:20421154-Oropharyngeal Neoplasms,
pubmed-meshheading:20421154-Quinazolines,
pubmed-meshheading:20421154-Radiotherapy Dosage,
pubmed-meshheading:20421154-Salvage Therapy,
pubmed-meshheading:20421154-Survival Rate
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
|
|
pubmed:affiliation |
Department of Medical Oncology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil. herchenhorn@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
